北京义翘神州

抗体偶联药物(ADCs)是一类将细胞毒性药物与单克隆抗体通过连接子偶联形成的抗肿瘤药物,它结合了细胞毒性药物的高效杀伤力和单克隆抗体的高度特异性靶向能力,在癌症治疗方面,拥有巨大的潜力。

选择合适的靶点是ADC药物成功开发的第一步。理想的靶点应是肿瘤特异性的,在正常组织细胞中很少表达;靶点与相应抗体结合后应通过内吞作用内化,以促进ADC药物进入肿瘤细胞,并通过适当的细胞内转运途径释放细胞毒性药物;此外,靶点应相对稳定,不易发生突变,这样可以降低ADC耐药性的产生。

义翘神州已开发出一系列ADC药物靶点蛋白产品,包含热门药物靶点如HER-2TROP-2Nectin-4EGFRCD19BCMA,以及新兴靶点如EphA3GFRA1CLEC7A等。这些靶点蛋白产品均经过抗体结合活性验证,并且具备多种属、多标签选择的特点,全面支持ADC药物研发。

产品优势

蛋白产品覆盖 90+ 热门ADC药物靶点

结合活性经抗体药验证

HEK293表达,重组蛋白更接近天然构象

多种属,支持种属交叉验证

多标签覆盖

高纯度:经SDS-PAGE & SEC-HPLC验证

高生物活性:细胞活性和抗体结合活性(ELISA、SPR/BLI)

高稳定性,高批间一致性

严格的质量控制体系:ISO 9001/ISO 13485/GMP质量体系认证

提供Biotin定点标记蛋白(AVI tag)

 

明星产品推荐

货号 靶点 种属 表达宿主 SEC-HPLC 纯度  活性
10904-H08H CD73/NT5E Human HEK293 Cells ≥ 95% ELISA, BLI
10620-H08H BCMA Human HEK293 Cells ≥ 95% ELISA, BLI, FACS
10818-H08H CD38 Human HEK293 Cells ≥ 95% ELISA, SPR
10774-H08H CD40/TNFRSF5 Human HEK293 Cells ≥ 95% ELISA, BLI
12283-H08H CD47 Human HEK293 Cells ≥ 95% ELISA, SPR, BLI
10692-H08H c-MET/HGFR Human HEK293 Cells ≥ 90% ELISA
11159-H08H CTLA-4 Human HEK293 Cells ≥ 95% ELISA, SPR, BLI
10694-H08H EpCAM/TROP1 Human HEK293 Cells ≥ 90% Cellular Activity
13926-H08H EphA2 Human HEK293 Cells ≥ 90% ELISA
10464-H07H FAP Human HEK293 Cells ≥ 90% Enzymatic Activity
10164-H08H IGF1R Human HEK293 Cells > 90% (SDS-PAGE) ELISA, SPR, BLI
15786-H08H LRRC15 Human HEK293 Cells > 95% (SDS-PAGE) ELISA
13128-H08H1 Mesothelin Human HEK293 Cells ≥ 95% (SDS-PAGE) ELISA, BLI
19771-H08H Nectin-4 Human HEK293 Cells > 95% ELISA, BLI
15877-H07H PSMA/FOLH1 Human HEK293 Cells > 95% (SDS-PAGE) ELISA
11020-H07H TFR1/CD71 Human HEK293 Cells > 90% ELISA
10428-H08H TROP-2 Human HEK293 Cells > 96% (SDS-PAGE) ELISA, BLI
 
 

ADC靶点蛋白应用案例

ADC药物IMMU-132的交叉反应和结合活性检测(ELISA & SPR)

引用产品: Human TROP-2 Protein (Cat#: 10428-H08H); Mouse TROP-2 Protein (Cat#: 50922-M08H)

The structure of IMMU-132 (a). Specificity of hRS7 for human Trop-2 (yellow curves) and murine Trop-2 (red curves) (b). The binding of IMMU-132 to Trop-2 was analyzed by surface plasmon resonance (BIACORE) (c).

Source: https://doi.org/10.3390/ph13090245; https://doi.org/10.1021/acs.bioconjchem.5b00223

 
 

新型抗肿瘤药物FDCs(Fab drug conjugates)与c-MET蛋白的结合活性检测(ELISA)

引用产品: Human c-MET/HGFR Protein (Cat#: 10692-H08H)

Binding affinity determination via ELISA of the anti-cMET Fab/IgG and their corresponding drug conjugates.

Source: https://doi.org/10.1080/14712598.2023.2292633

产品验证数据

HER2

 

Claudin 18.2

 

GFRA1

 

Human Her2/ERBB2 Protein

His Tag, Biotinylated
(Cat#:10004-H08H-B


Three independent lots of Biotinylated Recombinant Human ERBB2 Protein (His Tag) (Cat#: 10004-H08H-B) have identical bioactivity.

 

Human Full-length Claudin 18.2 Protein

VLP, fluorescent
(Cat#:30025-HNAH1


Immobilized human Claudin18.2-VLP (Full Length) protein, fluorescent (Cat: 30025-HNAH1) at 5 μg/mL (100 μL/well) can bind anti-human claudin18.2 antibody, human IgG1.

 

GFR Alpha-1/GFRA1 Protein

Rat, His Tag
(Cat#: 80021-R02H


Immobilized rat His-GDNF (78-211) (Cat: 80050-R07B) at 10 μg/ml (100 μl/well) can bind rat GFRA1-Fc.

请从上面以上列表中查询所需产品,或直接联系我们:
北京义翘神州科技股份有限公司

电话:400-890-9989
邮箱:marketing@sinobiological.cn
官网:cn.sinobiological.com
地址:北京市北京经济技术开发区科创十街18号院9号楼

北京义翘神州
关注"义翘神州"
获取更多资讯与促销信息
本网页由义翘神州委托 生物通 制作
北京义翘神州科技股份有限公司拥有以上广告资料(包括但不限于图片和文字)的版权